Large B-cell lymphomas, with an estimated 150,000 new cases annually worldwide, represent almost 30% of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy ...

A 92-year-old man with a history of diffuse large B-cell lymphoma treated with chemoradiotherapy, and later with radiotherapy for an isolated cutaneous relapse with complete response, presented with a ...

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age Safety and efficacy of polatuzumab vedotin with ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...

Around 30% to 40% of people with diffuse large B-cell lymphoma (DLBCL) experience a relapse after remission, and 83% of those who relapse have symptoms. Relapse symptoms can be the same as those that ...

Intravascular large B-cell lymphoma (IVLBCL) is a very rare, aggressive non-Hodgkin’s lymphoma. With IVLBCL, lymphoma cells build up in small blood vessels, which can block blood flow and harm organs.

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Abbreviations: AKT, protein kinase B; BAD, BCL2-associated death promoter; BAK, BCL2 antagonist killer; BAX, BCL2-associated X protein; BCL, B-cell lymphoma; BTK ...

Diffuse large B-cell lymphoma (DLBCL) stage 4 is an advanced cancer. Despite its aggressive nature, DLBCL usually responds well to treatment, and new therapies are being developed to help improve ...

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...